por John R. Fischer
, Senior Reporter | September 27, 2018
Le Bonheur Children’s Hospital in Memphis, Tennessee has become the first in the world to install TRIUX neo, that latest generation of magnetoencephalography (MEG) solutions designed by MEGIN, for functional brain imaging.
Capable of mapping the human brain, the noninvasive approach is used to assess complex neurological disorders and collect information to confirm diagnoses when other imaging modalities prove inconclusive, thereby increasing accuracy in surgery and minimizing the risk of neurological deficit.
"The system's ultra-resilient ARMOR(tm) sensors and electronics improve the ability to localize brain activity. The new system is also easily adjustable for the ideal ergonomic position of a child or adult patient and offers the most positioning options available in any MEG device, allows for almost any patient type to be scanned," Janne Huhtala, CEO of MEGIN, told HCB News. "In addition, TRIUX neo can be adjusted at any time during the scan, which would previously could cause a delay in older systems."
Numed, a well established company in business since 1975 provides a wide range of service options including time & material service, PM only contracts, full service contracts, labor only contracts & system relocation. Call 800 96 Numed for more info.
“Le Bonheur Children’s has a world-class neuroscience program. They are leaders in implementing innovative technologies that translate to better care and improved outcomes,” said Huhtala in a statement. “We are honored to be working with their amazing team of clinicians and researchers as we look to expand the clinical impact of our technology.”
Used to localize epileptic activity between seizures and significant healthy tissues in the cortex that must be preserved during surgery, MEG solutions are designed with a superconducting quantum interference device (SQUID) array that, when placed close to the scalp, detects weak magnetic fields originating from electrical activity within the brain.
Potential applications for its use include planning the placement of intracranial electrodes; evaluations of epilepsy; accurate localization of cortical tissues for procedures such as tumor removal; and presurgical mapping of visual, auditory, somatosensory and motor cortex areas.
The solution was previously introduced
last December by Elekta, a supplier of MEG technology, at the American Epilepsy Society (AES) Annual Meeting in Washington, D.C., along with the new commercial name for its MEG business, MEGIN, before being acquired
by York Instruments in July.
Utilizing high sensitivity, TRIUX neo is able to detect and localizes neural events generated in the brain with millimeter accuracy and millisecond resolution.
When merged with structural MR imaging, it enables users to view critical areas of the brain, including those that enable humans to see, talk, or move, collecting data to help clinicians verify that diagnoses are accurate.
Its use increases the safety of children during surgery, ensuring fewer complications, and opens up the option of surgery for epileptic pediatric patients who previously may not have been recognized as surgical candidates, according to Huhtala.
"The clinical value of MEG is that it provides detailed information to potentially minimize neurological deficit during surgery or provide insight that may change the course of how patients are managed as a result of being able to detect the brain's neuronal activity," he said.